Evidence map›Paper›PMID 39338298›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Anticancer Activity of Imidazolyl Gold(I/III) Compounds in Non-Small Cell Lung Cancer Cell Lines.

Rossana Galassi, Nicola Sargentoni, Sofia Renzi, Lorenzo Luciani, Caterina Bartolacci, Prasad Pattabhi, Cristina Andreani, Stefania Pucciarelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rossana GalassiChemistry Division, School of Science and Technology, University of Camerino, ChIP Via Madonna delle Carceri, 62032 Camerino, Italy.ORCID 0000-0002-8025-9615
Nicola SargentoniChemistry Division, School of Science and Technology, University of Camerino, ChIP Via Madonna delle Carceri, 62032 Camerino, Italy.ORCID 0009-0009-2735-3440
Sofia RenziSchool of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino, Italy.
Lorenzo LucianiChemistry Division, School of Science and Technology, University of Camerino, ChIP Via Madonna delle Carceri, 62032 Camerino, Italy.ORCID 0000-0002-9000-7454
Caterina BartolacciUniversity of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45219, USA.ORCID 0000-0003-2002-7721
Prasad PattabhiUniversity of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45219, USA.
Cristina AndreaniUniversity of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45219, USA.ORCID 0000-0003-3245-670X
Stefania PucciarelliSchool of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino, Italy.ORCID 0000-0003-2137-5517

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a leading cause of cancer-related death worldwide that needs updated therapies to contrast both the serious side effects and the occurrence of drug resistance. A panel of non-small cell lung cancer (NSCLC) cells were herein employed as cancer models. Eight structurally related gold(I) and gold(III) complexes with NHC and halides or triphenylphosphane ligands were investigated as lung cancer cell growth inhibitors. As expected, gold compounds with PPh

Indexed as

dihydrofolate reductasegold carbene complexesgold(I) and gold(III)gold phosphane compoundsKRAS mutant cellslung cancermetal-based anticancerthioredoxin reductase

Identifiers

PMID39338298
PMCPMC11435220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.